February 27, 2026 | Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss safety considerations associated with subcutaneous amivantamab in EGFR-mutated NSCLC. Neal reviews how this formulation has helped address infusion-related reactions associated with intravenous administration. Goldberg emphasizes that other toxicity considerations remain key beyond infusion-related reactions.
Related Posts
Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC
Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management
How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC
